<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6858833/results/search/disease/results.xml">
  <result pre="and 5 of our Terms ( https://www.dovepress.com/terms.php). Abstract Abstract Pediatric-onset" exact="multiple sclerosis" post="(POMS) is an immune-mediated, demyelinating, neurodegenerative disease that accounts"/>
  <result pre="immune-mediated, demyelinating, neurodegenerative disease that accounts for 3–5% of all" exact="multiple sclerosis" post="(MS) cases. Although evidence suggests that it has similar"/>
  <result pre="disease-modifying therapy demyelinating disease S1P receptor modulator neuroimmunology pediatric onset" exact="multiple sclerosis" post="table-count: ref-count: page-count: Introduction Multiple sclerosis (MS) is an"/>
  <result pre="MS cases occurring in childhood or adolescence. 1– 3 Pediatric-onset" exact="multiple sclerosis" post="(POMS) is defined as onset of disease prior to"/>
  <result pre="were transient cases of lymphopenia and cough, as well as" exact="urinary tract infection" post="and leg paresthesia. Compared to a historical cohort from"/>
  <result pre="events were observed with first dose and no lymphopenia or" exact="macular edema" post="were reported during periods of treatment. There were single"/>
  <result pre="genital herpes and upper respiratory infection, and 2 cases of" exact="urinary tract infection." post="Most recently Egyptian registry data of 186 POMS patients"/>
  <result pre="serious adverse events. There were also single cases of agranulocytosis," exact="second-degree atrioventricular block," post="elevated alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal"/>
  <result pre="adverse events. There were also single cases of agranulocytosis, second-degree" exact="atrioventricular block," post="elevated alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal"/>
  <result pre="alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal necrosis, and" exact="macular edema" post="reported, among others. Serious infections occurred in 4 fingolimod"/>
  <result pre="Fingolimod is an oral DMT for the treatment of relapsing-remitting" exact="multiple sclerosis." post="It was approved in September 2010 by FDA to"/>
  <result pre="observational studies, there were a few cases of seizures and" exact="leukopenia" post="among others in the PARADIGMS trial. In terms of"/>
  <result pre="infectious complications were most commonly reported. It is believed that" exact="leukopenia" post="and lymphopenia, as a result of fingolimod’s mechanism of"/>
  <result pre="less than 6% in PARADIGMS. Despite only 1 case of" exact="macular edema" post="reported in the PARADIGMS trial, similar screening measures for"/>
  <result pre="edema reported in the PARADIGMS trial, similar screening measures for" exact="macular edema," post="as well as for bradyarrythmia and herpes virus infection"/>
  <result pre="gastrointestinal necrosis (intussusception or necrotic bowel), head injury, humerus fracture," exact="hypersensitivity" post="vasculitis, migraine, migraine without aura, multiple sclerosis plaque, muscular"/>
  <result pre="or necrotic bowel), head injury, humerus fracture, hypersensitivity vasculitis, migraine," exact="migraine" post="without aura, multiple sclerosis plaque, muscular weakness, rectal tenesmus,"/>
  <result pre="head injury, humerus fracture, hypersensitivity vasculitis, migraine, migraine without aura," exact="multiple sclerosis" post="plaque, muscular weakness, rectal tenesmus, 2° atrioventricular block, and"/>
  <result pre="without aura, multiple sclerosis plaque, muscular weakness, rectal tenesmus, 2°" exact="atrioventricular block," post="and small-intestinal obstruction (0.9%) Huppke et al 19 Observational,"/>
  <result pre="al 21 Observational, 8 patients 50% None Abbreviations: POMS, pediatric-onset" exact="multiple sclerosis;" post="AE, adverse events; RCT, randomized controlled trial; ALT, alanine"/>
  <result pre=", Jaffin S , Healy B . Demographics of pediatric-onset" exact="multiple sclerosis" post="in an MS center population from the Northeastern United"/>
  <result pre="10.1212/WNL.0000000000003028 27572865 5. Chitnis T . Disease-modifying therapy of pediatric" exact="multiple sclerosis." post="Neurotherapeutics . 2013; 10: 89– 96. doi: 10.1007/s13311-012-0158-1 23224690"/>
  <result pre="I , von Kries R , Hanefeld F . Paediatric" exact="multiple sclerosis" post="and acute disseminated encephalomyelitis in Germany: results of a"/>
  <result pre="Kries R , Hanefeld F . Paediatric multiple sclerosis and" exact="acute disseminated encephalomyelitis" post="in Germany: results of a nationwide survey . Eur"/>
  <result pre=", Hanefeld F . Paediatric multiple sclerosis and acute disseminated" exact="encephalomyelitis" post="in Germany: results of a nationwide survey . Eur"/>
  <result pre="DL , et al. Clinical, environmental, and genetic determinants of" exact="multiple sclerosis" post="in children with acute demyelination: a prospective national cohort"/>
  <result pre=". Interactions between genetic, lifestyle and environmental risk factors for" exact="multiple sclerosis" post=". Nat Rev Neurol . 2017; 13( 1): 25–"/>
  <result pre="J , Weinstock-Guttman B , et al. Distinct effects of" exact="obesity" post="and puberty on risk and age at onset of"/>
  <result pre="B cell autoimmunity to a myelin surface antigen in pediatric" exact="multiple sclerosis" post=". J Immunol . 2009; 183( 6): 4067– 4076."/>
  <result pre="and sex hormones in determining the onset and outcome of" exact="multiple sclerosis" post=". Mult Scler . 2014; 20( 5): 520– 526."/>
  <result pre="et al. Trial of fingolimod versus interferon beta-1a in pediatric" exact="multiple sclerosis." post="N Engl J Med . 2018; 379( 11): 1017–"/>
  <result pre="Ellenberger D , et al. Therapy of highly active pediatric" exact="multiple sclerosis." post="Mult Scler . 2019; 25( 1): 72– 80. doi:"/>
  <result pre="AA , et al. Fingolimod prescribed for the treatment of" exact="multiple sclerosis" post="in patients younger than age 18 years . Pediatr"/>
  <result pre=", Abdel-Naseer M , Shalaby NM , et al. Pediatric-onset" exact="multiple sclerosis" post="in Egypt: a multi-center registry of 186 patients. Neuropsychiatr"/>
  <result pre=", et al. Disease reactivation after fingolimod discontinuation in two" exact="multiple sclerosis" post="patients. J Neurol . 2013; 260( 1): 327– 329."/>
  <result pre="Amato MP . Rebound after Fingolimod suspension in a pediatric-onset" exact="multiple sclerosis" post="patient. J Neurol . 2013; 260( 6): 1675– 1677."/>
 </snippets>
</snippetsTree>
